PR Newswire
DUBLIN, May 1, 2024
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –
– Oncology revenues grew 13% year-over-year –
– Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier –
– Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 –
– 2024 total revenue guidance affirmed at $4.0 to $4.2 billion –
DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.
"In the first quarter of 2024, we delivered combined double-digit year-over-year growth from our key growth drivers: Xywav, Epidiolex and Rylaze. We also significantly advanced our zanidatamab program with the completion of the BLA for 2L BTC," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We believe the robust growth in patients benefitting from Xywav underscores the appreciation physicians and patients have for the long-term health benefits of reducing sodium and expect Xywav to remain the oxybate of choice. We see continued demand for Rylaze as the only non-E. coli asparaginase regimen that provides sustained activity throughout the course of treatment, and we expect continued growth of Epidiolex to be driven by geographic expansion, optimized dosing and data demonstrating its beyond-seizure benefits. Growing and durable revenues from Xywav, Epidiolex and Rylaze, coupled with our pipeline progress, drive our confidence in delivering on our guidance and objectives for 2024."
Key Highlights
Business Updates
Key Commercial Products
Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
Xywav for Narcolepsy:
Xywav for Idiopathic Hypersomnia (IH):
Xyrem® (sodium oxybate) oral solution:
High-Sodium Oxybate Authorized Generic (AG) Royalties:
Epidiolex/Epidyolex (cannabidiol):
Rylaze/Enrylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn):
Zepzelca (lurbinectedin):
Key Pipeline Highlights
Zanidatamab:
Suvecaltamide (JZP385):
Financial Highlights
| Three Months Ended March 31, | ||
(In thousands, except per share amounts) | 2024 | | 2023 |
Total revenues | $ 901,983 | | $ 892,812 |
GAAP net income (loss) | $ (14,618) | | $ 69,420 |
Non-GAAP adjusted net income | $ 182,215 | | $ 285,261 |
GAAP earnings (loss) per share | $ (0.23) | | $ 1.04 |
Non-GAAP adjusted EPS | $ 2.68 | | $ 3.95 |
GAAP net loss for 1Q24 was $(14.6) million, or $(0.23) per diluted share, compared to a GAAP net income of $69.4 million, or $1.04 per diluted share, for 1Q23.
Non-GAAP adjusted net income for 1Q24 was $182.2 million, or $2.68 per diluted share, compared to a Non-GAAP adjusted net income of $285.3 million, or $3.95 per diluted share, for 1Q23.
Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
| Three Months Ended March 31, | ||
(In thousands) | 2024 | | 2023 |
Xywav | $ 315,300 | | $ 277,761 |
Xyrem | 64,232 | | 178,130 |
Epidiolex/Epidyolex | 198,716 | | 188,909 |
Sativex | 2,735 | | 7,098 |
Total Neuroscience | 580,983 | | 651,898 |
Rylaze/Enrylaze | 102,750 | | 85,927 |
Zepzelca | 75,100 | | 67,181 |
Defitelio/defibrotide | 47,676 | | 39,079 |
Vyxeos | 32,023 | | 36,700 |
Total Oncology | 257,549 | | 228,887 |
Other | 3,570 | | 3,434 |
Product sales, net | 842,102 | | 884,219 |
High-sodium oxybate AG royalty revenue | 49,947 | | 2,096 |
Other royalty and contract revenues | 9,934 | | 6,497 |
Total revenues | $ 901,983 | | $ 892,812 |
Total revenues increased 1% in 1Q24 compared to the same period in 2023, driven by higher Oncology product sales of 13%, primarily due to continued growth in Rylaze/Enrylaze, which increased 20% to $102.8 million in 1Q24 compared to the same period in 2023, partially offset by lower neuroscience revenues. Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, of $630.9 million decreased in 1Q24 compared to the same period in 2023, primarily due to decreased Xyrem revenues, reflecting the adoption of Xywav by existing Xyrem patients, high-sodium oxybate competition and changes to formulary coverage, partially offset by increased royalty revenue received on net sales of high-sodium oxybate AG products and increased Xywav and Epidiolex/Epidyolex net product sales.
Operating Expenses and Effective Tax Rate
| Three Months Ended March 31, | ||
(In thousands, except percentages) | 2024 Werbung Mehr Nachrichten zur Jazz Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. |